Table 3 Relative weight of shared component between adjuvant therapies for separate cohort model adjusted for all other predictor variables
| Â | Median posterior relative weights [95 % CrIa] | ||
|---|---|---|---|
| Â | Radiotherapy | Chemotherapy | Hormonal therapy |
At age 40–49 |  |  |  |
Radiotherapy | 1.00 | — | — |
Chemotherapy | 0.57 [0.31, 0.94] | 1.00 | — |
Hormonal therapy | 0.86 [0.57, 1.29] | 1.51 [0.92, 2.66] | 1.00 |
At age 50–59 |  |  |  |
Radiotherapy | 1.00 | — | — |
Chemotherapy | 0.40 [0.23, 0.65] | 1.00 | — |
Hormonal therapy | 0.87 [0.63, 1.19] | 2.16 [1.36, 3.63] | 1.00 |
At age 60–69 |  |  |  |
Radiotherapy | 1.00 | — | — |
Chemotherapy | 0.58 [0.31, 0.95] | 1.00 | — |
Hormonal therapy | 0.81 [0.58, 1.11] | 1.39 [0.84, 2.62] | 1.00 |
At age 70–89 |  |  |  |
Radiotherapy | 1.00 | — | — |
Chemotherapy | 0.92 [0.48, 1.55] | 1.00 | — |
Hormonal therapy | 0.74 [0.50, 1.08] | 0.80 [0.48, 1.55] | 1.00 |
Localised tumour | Â | Â | Â |
Radiotherapy | 1.00 | — | — |
Chemotherapy | 0.34 [0.18, 0.58] | 1.00 | — |
Hormonal therapy | 0.81 [0.61, 1.05] | 2.42 [1.39, 4.47] | 1.00 |
Advanced tumour | Â | Â | Â |
Radiotherapy | 1.00 | — | — |
Chemotherapy | 0.86 [0.63, 1.18] | 1.00 | — |
Hormonal therapy | 0.86 [0.61, 1.17] | 0.99 [0.72, 1.41] | 1.00 |